IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v13y2022i1d10.1038_s41467-022-30217-7.html
   My bibliography  Save this article

N6-methyladenosine regulated FGFR4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancer

Author

Listed:
  • Yutian Zou

    (Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine)

  • Shaoquan Zheng

    (Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine)

  • Xinhua Xie

    (Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine)

  • Feng Ye

    (Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine)

  • Xiaoqian Hu

    (School of Biomedical Sciences, Faculty of Medicine, The University of Hong Kong)

  • Zhi Tian

    (College of Pharmacy, University of South Florida)

  • Shu-Mei Yan

    (Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine)

  • Lu Yang

    (Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine)

  • Yanan Kong

    (Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine)

  • Yuhui Tang

    (Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine)

  • Wenwen Tian

    (Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine)

  • Jindong Xie

    (Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine)

  • Xinpei Deng

    (Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine)

  • Yan Zeng

    (Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine)

  • Zhe-Sheng Chen

    (College of Pharmacy and Health Sciences, St. John’s University)

  • Hailin Tang

    (Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine)

  • Xiaoming Xie

    (Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine)

Abstract

Intrinsic and acquired anti-HER2 resistance remains a major hurdle for treating HER2-positive breast cancer. Using genome-wide CRISPR/Cas9 screening in vitro and in vivo, we identify FGFR4 as an essential gene following anti-HER2 treatment. FGFR4 inhibition enhances susceptibility to anti-HER2 therapy in resistant breast cancer. Mechanistically, m6A-hypomethylation regulated FGFR4 phosphorylates GSK-3β and activates β-catenin/TCF4 signaling to drive anti-HER2 resistance. Notably, suppression of FGFR4 dramatically diminishes glutathione synthesis and Fe2+ efflux efficiency via the β-catenin/TCF4-SLC7A11/FPN1 axis, resulting in excessive ROS production and labile iron pool accumulation. Ferroptosis, a unique iron-dependent form of oxidative cell death, is triggered after FGFR4 inhibition. Experiments involving patient-derived xenografts and organoids reveals a synergistic effect of anti-FGFR4 with anti-HER2 therapy in breast cancer with either intrinsic or acquired resistance. Together, these results pinpoint a mechanism of anti-HER2 resistance and provide a strategy for overcoming resistance via FGFR4 inhibition in recalcitrant HER2-positive breast cancer.

Suggested Citation

  • Yutian Zou & Shaoquan Zheng & Xinhua Xie & Feng Ye & Xiaoqian Hu & Zhi Tian & Shu-Mei Yan & Lu Yang & Yanan Kong & Yuhui Tang & Wenwen Tian & Jindong Xie & Xinpei Deng & Yan Zeng & Zhe-Sheng Chen & Ha, 2022. "N6-methyladenosine regulated FGFR4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancer," Nature Communications, Nature, vol. 13(1), pages 1-18, December.
    • Handle: RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-30217-7
    DOI: 10.1038/s41467-022-30217-7
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-022-30217-7
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-022-30217-7?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Nicholas Yagoda & Moritz von Rechenberg & Elma Zaganjor & Andras J. Bauer & Wan Seok Yang & Daniel J. Fridman & Adam J. Wolpaw & Inese Smukste & John M. Peltier & J. Jay Boniface & Richard Smith & Ste, 2007. "RAS–RAF–MEK-dependent oxidative cell death involving voltage-dependent anion channels," Nature, Nature, vol. 447(7146), pages 865-869, June.
    2. Sunwang Xu & Ming Zhan & Cen Jiang & Min He & Linhua Yang & Hui Shen & Shuai Huang & Xince Huang & Ruirong Lin & Yongheng Shi & Qiang Liu & Wei Chen & Man Mohan & Jian Wang, 2019. "Genome-wide CRISPR screen identifies ELP5 as a determinant of gemcitabine sensitivity in gallbladder cancer," Nature Communications, Nature, vol. 10(1), pages 1-14, December.
    3. Yuexin Zhou & Shiyou Zhu & Changzu Cai & Pengfei Yuan & Chunmei Li & Yanyi Huang & Wensheng Wei, 2014. "High-throughput screening of a CRISPR/Cas9 library for functional genomics in human cells," Nature, Nature, vol. 509(7501), pages 487-491, May.
    4. Liyun Luo & Zhijie Zhang & Ni Qiu & Li Ling & Xiaoting Jia & Ying Song & Hongsheng Li & Jiansheng Li & Hui Lyu & Hao Liu & Zhimin He & Bolin Liu & Guopei Zheng, 2021. "Disruption of FOXO3a-miRNA feedback inhibition of IGF2/IGF-1R/IRS1 signaling confers Herceptin resistance in HER2-positive breast cancer," Nature Communications, Nature, vol. 12(1), pages 1-16, December.
    5. Bo Li & Sara M. Clohisey & Bing Shao Chia & Bo Wang & Ang Cui & Thomas Eisenhaure & Lawrence D. Schweitzer & Paul Hoover & Nicholas J. Parkinson & Aharon Nachshon & Nikki Smith & Tim Regan & David Far, 2020. "Genome-wide CRISPR screen identifies host dependency factors for influenza A virus infection," Nature Communications, Nature, vol. 11(1), pages 1-18, December.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Yi-Yu Chen & Jing-Yu Ge & Si-Yuan Zhu & Zhi-Ming Shao & Ke-Da Yu, 2022. "Copy number amplification of ENSA promotes the progression of triple-negative breast cancer via cholesterol biosynthesis," Nature Communications, Nature, vol. 13(1), pages 1-16, December.
    2. Jun-Yan Li & Yin Zhao & Sha Gong & Miao-Miao Wang & Xu Liu & Qing-Mei He & Ying-Qin Li & Sheng-Yan Huang & Han Qiao & Xi-Rong Tan & Ming-Liang Ye & Xun-Hua Zhu & Shi-Wei He & Qian Li & Ye-Lin Liang & , 2023. "TRIM21 inhibits irradiation-induced mitochondrial DNA release and impairs antitumour immunity in nasopharyngeal carcinoma tumour models," Nature Communications, Nature, vol. 14(1), pages 1-17, December.
    3. Caterina Bartolacci & Cristina Andreani & Gonçalo Vale & Stefano Berto & Margherita Melegari & Anna Colleen Crouch & Dodge L. Baluya & George Kemble & Kurt Hodges & Jacqueline Starrett & Katerina Poli, 2022. "Targeting de novo lipogenesis and the Lands cycle induces ferroptosis in KRAS-mutant lung cancer," Nature Communications, Nature, vol. 13(1), pages 1-19, December.
    4. Joseph D. Trimarco & Sarah L. Nelson & Ryan R. Chaparian & Alexandra I. Wells & Nathan B. Murray & Parastoo Azadi & Carolyn B. Coyne & Nicholas S. Heaton, 2022. "Cellular glycan modification by B3GAT1 broadly restricts influenza virus infection," Nature Communications, Nature, vol. 13(1), pages 1-15, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-30217-7. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.